MedTrace Logo

Evaluation of ClearLLab Leukemia and Lymphoma Panels

NCT03413644 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 482

Last updated 2018-07-13

No results posted yet for this study

Summary

Multi-center study of specimens from subjects presenting to the flow cytometry laboratory as part of their standard of care for hematological diseases work-up.

Conditions

  • Leukemia-Lymphoma

Interventions

DIAGNOSTIC_TEST

Flow Cytometry

Immunophenotyping of residual clinical samples tested with ClearLLab diagnostic reagent on a specified Flow Cytometer

Sponsors & Collaborators

  • Beckman Coulter, Inc.

    lead INDUSTRY

Principal Investigators

  • Adrian Padurean, MD · NeoGenomics Laboratories, Inc.

  • Mike Keeney · London Health Sciences Center

  • Joanne Luider · Calgary Laboratory Services

  • Wolfgang Kern · Munich Leukemia Laboratory

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-14
Primary Completion
2018-04-27
Completion
2018-04-27
FDA Device
Yes

Countries

  • United States
  • Canada
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03413644 on ClinicalTrials.gov